Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Licensing Deal

Zymeworks Shares Jump 10% in 8 Days Since $813 Million Licensing Deal with Roche for ZW209

Zymeworks Enters $813 Million Licensing Deal with Roche for Cancer Therapeutic ZW209

+10.25% in 8 days $28.44 when we broke this story → $31.35 at 11:12 AM ET, 4 Nov 2026

Zymeworks Inc. has entered into a global collaboration and license agreement with Roche for ZW209, a trispecific T-cell engager targeting DLL3. The deal includes a $55 million upfront payment and transfers global development and commercialization rights to Roche following initial Phase 1a trials.

Scientist, drugstore, microscope, chemistry. Stock photo illustrating Zymeworks' licensing deal story.
Zymeworks Inc. · Healthcare · Photo: luvqs / Pixabay
Key numbers
Deal value$813M
Share of market cap40.3%
Share of annual revenue767.2%

Key highlights

  • Total potential transaction value reached $813 million including milestones
  • Zymeworks to receive immediate $55 million upfront non-refundable payment
  • Additional $40 million milestone payment due upon initiation of Phase 1b trial
  • Roche gains exclusive worldwide rights to ZW209 and related DLL3 compounds
  • Tiered royalties ranging from high-single digits to mid-teens on future net sales

What Is the Licensing Deal?

Roche has acquired exclusive global rights to develop and commercialize ZW209, a proprietary trispecific T-cell engager designed to target DLL3-expressing tumor cells. The agreement encompasses all research, manufacturing, and commercial activities for pharmaceutical products containing ZW209 or its derivatives. Under the technical terms, Zymeworks will remain responsible for conducting the Phase 1a monotherapy dose escalation trial at Roche's expense. Following this initial stage, Roche will assume full responsibility for the Phase 1b clinical trial and all subsequent global development and regulatory filings. The license becomes effective following clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Zymeworks Inc. share price · last month
Line chart of Zymeworks Inc.'s share price over the last month, from $25.54 on 19 Oct → $26.45 on 16 Nov; our story on 23 Oct at $28.44.

Down 7.0% since our story on 23 Oct: $28.44 when we broke it → $26.45 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$25.54
20 Oct$26.91
21 Oct$28.11
22 Oct$28.44
23 Oct$28.22
26 Oct$28.37
27 Oct$28.85
28 Oct$28.90
29 Oct$28.71
30 Oct$28.61
2 Nov$28.99
3 Nov$30.13
4 Nov$30.94
5 Nov$28.73
6 Nov$29.63
9 Nov$30.81
10 Nov$31.46
11 Nov$29.07
12 Nov$26.47
13 Nov$26.24
16 Nov$26.45

Licensing Terms

The financial framework provides Zymeworks with a $55 million upfront payment and a guaranteed $40 million payment upon the initiation of the Phase 1b trial. The company is also eligible to earn up to $718 million in additional research, development, and commercial milestones. Beyond these cash payments, Zymeworks will receive tiered royalties on global net sales, with rates spanning from high-single digits to the mid-teens. These royalties are protected by a patent estate extending into the 2040s. For a five-year period or until the start of a Phase 3 study, Zymeworks is restricted from developing competing T-cell engagers targeting DLL3-expressing cells.

Strategic Fit

This collaboration follows Zymeworks' strategy of advancing differentiated therapeutic candidates internally while selectively partnering programs to mitigate clinical risk. By integrating Roche's manufacturing and commercial infrastructure, the company aims to accelerate ZW209's reach across various lung cancer indications. This deal complements Zymeworks' broader research portfolio, which includes multispecific T-cell engagers for solid and hematological tumors. The agreement also builds on recent financial moves, such as the $250 million royalty-backed note financing secured from Royalty Pharma in March 2026 and a research partnership with Gandeeva Therapeutics signed in June 2026.

Business Overview

  • Headquartered in Delaware with specialized R&D operations in Vancouver
  • Focused on multifunctional biotherapeutics for oncology and autoimmune diseases
  • Updated 2026 revenue guidance project totals between $278 million and $292 million
  • Anticipates $100 million milestone payment from Royalty Pharma in Q1 2027
  • Maintains a robust portfolio of multispecific antibody platforms and AIID programs

Management Perspective

“This collaboration allows us to continue advancing ZW209 through its initial clinical development while leveraging Roche’s complementary capabilities to accelerate and expand its development across indications and treatment settings.”

Adam Schayowitz, Ph.D., MBA, Executive Vice President and Head of R&D, Zymeworks
Earlier announcements by Zymeworks Inc.
DateAnnouncementAmount
18 Jun 2026Research partnership with Gandeeva Therapeutics to accelerate antibody drug discovery using cryo-EMSource: gandeeva.com–
02 Mar 2026Royalty-backed note financing agreement with Royalty Pharma secured by 30% of Ziihera royalty cash flowsSource: ir.zymeworks.com$250.0 Million
30 Oct 2025Three-Party Royalty Payment Agreement with BeOne Medicines and BeOne Pharmaceutical (Suzhou)Source: SEC filing–

Management commentary

“The agreement also reflects our broader strategy of generating innovative programs through our R&D engine and partnering selected assets in ways that share development risk while preserving meaningful participation in their future success.”

Adam Schayowitz, Ph.D., MBA, Executive Vice President and Head of R&D
Zymeworks Inc. · financial snapshot
Share price$28.44
Market cap$2.0B
Revenue (annual)$106M
1-month price change+3.17%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Zymeworks Inc. announcing an exclusive global license and collaboration agreement with Roche for ZW209.

Read the filing ↗

Track Zymeworks Inc. live

Get the next Zymeworks Inc. SEC filing seconds after it lands.

More in Partnerships

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.